Our Experience Olopatadine Treatment of Allergic Conjunctivitis in Children
https://doi.org/10.18008/1816-5095-2021-2-361-367
Abstract
The authors analyzed the treatment results of 53 patients (106 eyes) with allergic conjunctivitis. All patients received Olopatadine 0.2 % (Visallergol) in drops once a day during 1 month. All patients underwent the same tests: scraping from the conjunctiva for the presence of eosinophils, evaluation of the inflammation symptoms using 4-ball scale, biomicroscopy of cornea and conjunctiva with staining by lissamine green and tear film stability (Norn’s method). All of the above-mentioned tests were performed before the treatment, on 14-th day and after the course of therapy. The inflammatory reaction of conjunctiva, the amount of discharge in the conjunctival cavity and the staining of the conjunctiva with lissamine green decreased in all patients starting from the 14-th day of treatment. The maximal effectiveness of the drop was registered in patients with the chronic type of allergic conjunctivitis. The manifestation of the disease reduced significantly after 1 month of treatment, but it does not disappear completely. So it is necessary to continue therapy after 1 month. The laboratory methods of diagnosis confirm the effectiveness of Visallergol by disappearance of eosinophils in the conjunctiva scrapings. The secondary dry eye syndrome developed in all types of the allergic conjunctivitis and needs a long-term treatment. The maximal intensity of dry eye syndrome was registered in patients with chronic type of the allergic conjunctivitis. The drop can be used starting from 2 years old.
About the Authors
T. N. Vorontsova
“Polyclinic complex”
Russian Federation
Russian Federation
PhD, leading specialist in pediatric ophthalmology,
Moskovskiy ave., 22, St.-Petersburg 190013
M. V. Zaitseva
St.-Petersburg State Medical Institution “Diagnostic Centre No. 7 (eye) for adults and children”
Russian Federation
Russian Federation
ophthalmologist,
Mokhovaya str., 38, St.-Petersburg 191028
M. A. Chramtsova
St.-Petersburg State Medical Institution “Diagnostic Centre No. 7 (eye) for adults and children”
Russian Federation
Russian Federation
head of the Clinical diagnostic laboratory,
Mokhovaya str., 38, St.-Petersburg 191028
References
1. Maichuk Yu.F. Allergic conjunctivitis. The modern view of the clinical forms and diagnosis. Refractive surgery and ophthalmology = Refraktsionnaya khirurgiya i oftal’mologiya. 2010;10(2):46–49 (In Russ.).
2. Friedlander M.H. Current ocular therapy. Ed. F.T. Frannfelder, Roy F.H., Randall J., W.B. Saunders Comp. 2000. 323 p.
3. Sidorenko E.I., Guseva M.R., Astasheva I.B. Etiology, clinic, treatment and prevention of conjunctivitis in preschool and school-age children. Russian ophthalmology of children = Rossiiskaya detskaya oftal’mologiya. 2016;4:14–31 (In Russ.).
4. Abelson M.B., Mc–Garr P.J., Richard K.B. Textbook of ocular pharmacology. Ed. T.J. Zimmerman. Lippencott. 1997:609–634.
5. Markova E.Yu., Polunina E.G., Ioileva E.E. Allergic eye diseases in children. Modern view on pathogenesis and treatment. Ophthalmology in Russia = Oftalmologiya. 2017:14(2):125–129 (In Russ.). DOI: 10.18008/1816-50952017-2-125-129
6. Egorov E.A., Muratova N.V. Allergic eye diseases (clinic and treatment): a reference guide. Moscow, 1998. 62 p. (In Russ.).
7. Yanchenko S.V., Malyshev A.V., Sakhnov S.N., Bukina A.V. Clinical experience of using 0.2 % olopatadine in the treatment of allergic conjunctivitis. Ophthalmology in Russia = Oftalmologiya. 2019;16(3):378–385 (In Russ.). DOI: 10.18008/1816-5095-2019-3-378-385
8. Yani E.V., Pozdnyakova V.V., Seliverstova K.E. New possibilities of treatment of medicinal ophthalmic allergoses. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2017;10(3):108–112 (In Russ.).
9. Yani E.V., Vakhova E.S., Seliverstova K.E. Tactics of treatment of scleritis of rheumatoid Genesis. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2018;11(1):93–97 (In Russ.).
10. Zumbulidze N.G., Hokkanen V.M., Litvin I.B. Evaluation of the therapeutic effectiveness of combined anti-allergic drugs in monotherapy of allergic conjunctivitis. Ophthalmology in Russia = Oftalmologiya. 2020;17(1):117– 123 (In Russ.). DOI: 10.18008/1816-5095-2020-1-117-123
11. Lichtenshtein S., Paskin T., Edwards M., Wells D., Gross R., Robertson S. Safety and tolerability of olopatadin 0.2 % in children and adolescents. Journal of ocular pharmacology and therapeutics. 2007;23(4):137–141. DOI: 10.1089/jop2007.0013
12. Maychuk D.Yu., Chilingaryan L.B., Pronkin I.A., Grigoryan A.R. Use of artificial tears in cases of allergic conjunctivitis. Ophthalmology in Russia = Oftalmologiya. 2012:9(2):72–76 (In Russ.). DOI: 10.18008/1816-5095-2012-2-72-76
13. Iqbal M.H. Analysis of the role of tear substitutes in the eye relieve in chronic seasonal allergic conjunctivitis. Life Science Journal. 2013;10(2):616–620.
Review
For citations:
Vorontsova T.N., Zaitseva M.V., Chramtsova M.A. Our Experience Olopatadine Treatment of Allergic Conjunctivitis in Children. Ophthalmology in Russia. 2021;18(2):361-367. (In Russ.) https://doi.org/10.18008/1816-5095-2021-2-361-367
Views:
635
Email this article 